Kymera Therapeutics, Inc. Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

KYMR

Classement en actions #2158
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Prix de l'action
$111.01
Capitalisation boursière
$9.13B
Changement (1 jour)
-1.44%
Changement (1 an)
98.94%
Pays
US
Échange Kymera Therapeutics, Inc. (KYMR)

Catégorie

Healthcare
Historique du prix de l'action pour Kymera Therapeutics, Inc. (KYMR)
Prix de clôture le plus élevé : $109.30 le 2026-10-01

Prix de clôture le plus bas : $31.67 le 2020-08-01
Historique du prix de l'action de Kymera Therapeutics, Inc. de 2020 à 2026
Performance annuelle du prix de l'action
Année Performance
2026 (TTM) 12.16%
2025 87.59%
2024 77.01%
2023 -11.39%
2022 -52.05%
2021 -12.80%
2020 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
$536.91 25.90%
US
$230.20 757.36%
US
$137.83 -3.78%
AU
$291.76 2.51%
BE
$892.44 9.61%
NL